Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoKirkland Advises Bernhard Capital and its DOE and NNSA Platform on Purchase of SMSIRead MoreFacebookX.comPinterestLinkedinEmail48590
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoKirkland Advises Wind Point Partners on Sale of Handgards To Wynnchurch CapitalRead MoreFacebookX.comPinterestLinkedinEmail49290
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoKirkland Advises Benchmark on Securing $150 Million Revolving Credit FacilityRead MoreFacebookX.comPinterestLinkedinEmail49090
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoLatham & Watkins Advises Apollo on Concord’s Proposed US$1.4 Billion Acquisition of HipgnosisRead MoreFacebookX.comPinterestLinkedinEmail49290
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoLatham Advises Osaka Gas, Sumitomo Corporation and JOIN on Investment in AG&P LNG MarketingRead MoreFacebookX.comPinterestLinkedinEmail49190
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoLatham Advises Quadriga Capital on Sale of Kinetics GroupRead MoreFacebookX.comPinterestLinkedinEmail48990
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoLatham & Watkins Advises on Johnson Controls’ US$700 Million Senior Notes OfferingRead MoreFacebookX.comPinterestLinkedinEmail49090
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoLatham & Watkins Represents UL Solutions Inc. in Upsized US$1.08 Billion IPORead MoreFacebookX.comPinterestLinkedinEmail49690
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoLatham Advises DBAG Funds on Sale of Shares in SolvaresRead MoreFacebookX.comPinterestLinkedinEmail49290
Upvote0Points0PointsUpvotes:0Downvotes:0Total Votes:0DownvoteNitya VashishthaDeals1 year agoClifford Chance advises SciClone Pharmaceuticals on proposed HK$8.79 billion privatisation by GL CapitalRead MoreFacebookX.comPinterestLinkedinEmail49290
